The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC).
A. Berghoff
No relevant relationships to disclose
R. Bartsch
No relevant relationships to disclose
Z. Bago-Horvath
No relevant relationships to disclose
P. C. Dubsky
No relevant relationships to disclose
M. Rudas
No relevant relationships to disclose
U. Pluschnig
No relevant relationships to disclose
C. Wiltschke
No relevant relationships to disclose
M. Gnant
No relevant relationships to disclose
G. G. Steger
No relevant relationships to disclose
C. Zielinski
No relevant relationships to disclose